Transdiagnostic Versus Diagnosis-specific Cognitive-behavioral Therapy for Anxiety Disorders: a Randomized Controlled Pilot Study

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The primary aim of the pilot study is to investigate the feasibility of conducting a randomized controlled trial (RCT) comparing the effects of transdiagnostic and diagnosis-specific cognitive-behavioral therapy (CBT) for patients with anxiety disorders in routine psychiatric outpatient care in Stockholm, Sweden. It is hypothesized that an RCT is feasible in terms of recruitment, retention, therapist competence and adherence to treatments, and that the treatments are well received by participants.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• 18-65 years of age,

• Being able to speak Swedish without interpreter support,

• A principal diagnosis of panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, or posttraumatic stress disorder, and

• Pharmacological treatment (if any) that is stable six weeks prior to treatment start

Locations
Other Locations
Sweden
WeMind
RECRUITING
Stockholm
Contact Information
Primary
Benjamin Bohman, PhD
benjamin.bohman@ki.se
701713443
Backup
Fredrik Santoft, PhD
fredrik.santoft@ki.se
Time Frame
Start Date: 2022-03-01
Estimated Completion Date: 2025-09
Participants
Target number of participants: 76
Treatments
Experimental: Unified protocol
Transdiagnostic cognitive-behavioral therapy focusing on emotional processes central to the development and maintenance of anxiety disorders, particularly neuroticism.
Active_comparator: Diagnosis-specific cognitive-behavioral therapy
Cognitive-behavioral therapy specifically designed for a particular anxiety disorder as specified in evidence-based treatment protocols, which are commonly based on a specific theory or model of the development and maintenance of an anxiety disorder.
Sponsors
Leads: Karolinska Institutet

This content was sourced from clinicaltrials.gov